TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02578823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun®
Description: Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arcticgel™

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antipyretic treatment
Description: Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional antipyretic treatment
Description: Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
Study: NCT01759498

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HYDRO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HYDRO 2
Study: NCT01597037

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Script training
Description: 90 minutes/day, 6 days a week; includes 3 weeks of training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Script training
Description: 90 minutes/day, 6 days a week; includes 3 weeks of training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Script training
Description: 90 minutes/day, 6 days a week; includes 3 weeks of training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Script training
Description: 90 minutes/day, 6 days a week; includes 3 weeks of training
Study: NCT01518244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol maleate fixed combination
Study: NCT00514202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine SR
Description: 60 mg/day
Study: NCT03132168

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessments
Description: These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw
Description: Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized Anesthetic Care
Description: Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
Study: NCT04475822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carb diet
Description: Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbon diet and intermittent fasting group
Description: Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
Study: NCT04028999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluate the effects of the EO31 shoulder sling in adults post-stoke
Description: Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
Study: NCT03155295

Intervention type: OTHER
Intervention: Physical reality simulation
Description: Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.

Intervention type: OTHER
Intervention: Virtual reality simulation
Description: The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
Study: NCT03441568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Diprobase formulation (BAY987534)
Description: The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
Study: NCT03222076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00382850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen fundoplication
Study: NCT02106650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
Study: NCT00703508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg tablet
Description: Metformin 500 mg tablets; two tablets every 12 hours for 9 months
Study: NCT00428779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: running during 24 hours without sleep
Description: patients running during 24 hours without sleep

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no sleeping
Description: patients without sleep during 24 hours
Study: NCT00206830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triage Profiler S.O.B. Panel
Study: NCT03672305

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: c-Met/PD-L1 CAR-T cell injection
Description: injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
Study: NCT01470612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg tablets, BID, for at least 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg tablets, BID, for at least 12 months
Study: NCT00621569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension-The DASH diet
Description: The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention with no dietary component - information regarding useful life skills
Description: Participants receive information regarding useful life skills in a group setting
Study: NCT00807170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 300 mg as a once daily oral dose, 21 days
Study: NCT02432495

Intervention type: OTHER
Intervention: ANTERIOR SCREW FIXATION
Description: Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
Study: NCT00781248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NG Shield
Description: A device to reduce pain/discomfort related to nasogastric tube usage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NG Shield
Description: A device to reduce pain/discomfort related to nasogastric tube usage
Study: NCT02379754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicins
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Study: NCT02287402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-128
Description: AO-128 tablet
Study: NCT00691262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: transdermal
Study: NCT01568424

Intervention type: DEVICE
Group type: OTHER
Intervention: CentriMag RVAS placement
Description: Patients will be treated with a CentriMag RVAS
Study: NCT03711006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsules
Description: 25 daily multi-donor FMT Capsules for 50 days
Study: NCT03019744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeCFES-assisted task-oriented upper limb rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care task-oriented upper limb rehabilitation
Study: NCT04223024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT+Nimotuzumab
Description: concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCRT alone
Description: concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
Study: NCT02303873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).
Study: NCT04328571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OLE enzymatically treated
Description: OLE (Olive leaf extract ) enzymatically treated + maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OLE + probiotic
Description: OLE (Olive leaf extract) co-administered with probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OLE
Description: OLE (Olive leaf extract) + maltodextrin
Study: NCT04299451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open dialogue about CAM
Description: 1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
Study: NCT00251225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
Study: NCT02012569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-173
Description: Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
Study: NCT00251225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m\^2 administered IV on day 0
Study: NCT01913236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation intervention
Description: Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
Study: NCT03249740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-102
Description: Intravitreal injection of GB-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-102
Description: Intravitreal injection of GB-102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection of Aflibercept.
Study: NCT02827890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia Tab. 100mg
Description: Januvia Tab. 100mg\*1T/day for 5days, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia Tab. 100mg
Description: Januvia Tab. 100mg\*1T/day for 5days, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia Tab. 100mg + Duvie Tab. 0.5mg
Description: Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia Tab. 100mg + Duvie Tab. 0.5mg
Description: Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
Study: NCT02893995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow Dose Titration Group of Subcutaneous Treprostinil
Description: subcutaneous treprostinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid Dose Titration Group of Subcutaneous Treprostinil
Description: subcutaneous treprostinil
Study: NCT02919813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Group Cognitive BehaviorTherapy
Description: Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Seminars
Description: Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
Study: NCT01269281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Sumatriptan Succinate Tablets 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan Succinate Tablets 100 mg
Study: NCT01795742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Human-Powered Nebulizer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human-Powered Nebulizer
Study: NCT00016718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Description: Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Description: Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Description: Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Description: Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Description: Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
Study: NCT02432495

Intervention type: OTHER
Intervention: HALOV VEST IMMOBILIZATION
Description: Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
Study: NCT00113022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 24448
Description: 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
Study: NCT02012569

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01855334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Study: NCT01962519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Description: Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
Study: NCT02679209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix in putty form
Description: it is a type of bone graft from human cadavers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion chorion membrane
Description: A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
Study: NCT01855334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01928433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg i.v. once daily
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg i.v. once daily
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finafloxacin placebo i.v. once daily
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg tablets once daily
Description: Administered as four 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg tablets once daily
Description: Administered as four 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finafloxacin placebo tablets once daily
Description: Administered as four tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 400 mg i.v. twice daily
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin placebo i.v. twice daily
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin placebo i.v. twice daily
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500 mg oral twice daily
Description: Administered as two 250 mg capsules.
Study: NCT03600714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon lambda
Description: Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Oral prenylation inhibitor
Study: NCT01928433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin placebo oral twice daily
Description: Administered as two capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin placebo oral twice daily
Description: Administered as two capsules.
Study: NCT02317692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent training
Study: NCT02314442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-PCSSC
Description: Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study: NCT03768323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1X airtime incentive
Description: an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2X airtime incentive
Description: an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
Study: NCT00016718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Description: Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
Study: NCT01197417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium Sulfate
Description: 40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
Study: NCT01740869

Intervention type: OTHER
Group type: OTHER
Intervention: Stem cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cells
Study: NCT03600714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Booster of lonafarnib action
Study: NCT01198145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01197417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: (1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses